February 1, 2008

Skinvisible Appoints New Board Member

Brian Piwek to Assist in Generating New Retail Licensing Opportunities

Las Vegas, Nevada - February 1, 2008 - Skinvisible, Inc. (OTC Bulletin Board: SKVI / www.skinvisible.com), a pharmaceutical company focused on the discovery and development of patented dermatology products with their proprietary polymer delivery system Invisicare®, today announced that Mr. Brian Piwek has been selected as a new member of the Company's Board of Directors replacing Mr. Jost Steinbruchel, who has resigned as a Board Member. Mr. Steinburchel has been a Board Member since the company's inception in 1998 and the board and company officers wish to thank him for his valuable contribution during this time.

"We are delighted to have Mr. Brian Piwek join our Board of Directors, as he brings a great deal of experience and additional perspective that will be an asset to Skinvisible as we continue to implement our current initiatives," said Mr. Terry Howlett, President / CEO of Skinvisible. "We are entering an exciting phase at Skinvisible where we being the commercialization of our dermatology products with international licensees. Brian's business development and retail expertise will be invaluable as Skinvisible continues to pursue its growth goals."

Brian Piwek's experience and expertise is in the international retail industry. He was president of Overwaitea Foods supermarket from 1991 until 1997. In 1997 Brian accepted the position as Co-CEO with A&P Canada (The Great Atlantic & Pacific Tea Company Inc.) and in 2000 was appointed Chairman, President and CEO of A&P Canada. In late 2002 he moved to the U.S. as President and Chief Executive Officer of A&P US (New York Stock Exchange symbol "GAP") where he began the turnaround of North America's oldest retail food chain. Brian retired from A&P in July 2005. Brian has been recognized for his achievements throughout his career including "President of the Year" by the Jim Pattison Group for the outstanding financial performance of Overwaitea in 1993. Brian is an MBA graduate and has served on many voluntary boards.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent. www.skinvisible.com

About Invisicare®

Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. Other key benefits include its ability to gradually release active ingredients which reduces skin irritation and increases efficacy, it is non-occlusive on the skin and new patents can be issued for products formulated with Invisicare. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries. www.invisicare.com

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending December 31, 2007)

Press Release Index

Click here to join our mailing list.